Tech Company Financing Transactions
Arcus Biosciences Funding Round
Arcus Biosciences closed a $107 million Series C investment round on 11/14/2017. Backers included GV, Aisling Capital and BVF Partners.
Transaction Overview
Company Name
Announced On
11/14/2017
Transaction Type
Venture Equity
Amount
$107,000,000
Round
Series C
Investors
Proceeds Purpose
The proceeds from this financing will be used for the advancement of Arcus's clinical programs for AB928, a first-in-class dual adenosine receptor antagonist, and AB122, a PD-1 antibody.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3928 Point Eden Way
Hayward, CA 94545
USA
Hayward, CA 94545
USA
Phone
Undisclosed
Website
Email Address
Overview
Arcus Biosciences (NYSE: RCUS) The field of immuno-oncology (or cancer immunotherapy) has exploded in the past decade. Cancer immunotherapies generally work by interfering with the inhibitory signals produced by tumors against certain elements of the immune system. Arcus is initially developing drug therapies for small molecules along the ATP-adenosine pathway.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Terry Rosen
President
Juan Jaen
Vice President
Andrew Pennell
Vice President
Jay Powers
Vice President
Ulrike Schindler
Vice President
Nigel Walker
VP - Bus. Development
Timothy Sullivan
VP - Engineering
Steve Young
Browse more venture capital transactions:
Prev: 11/14/2017: ThreatQuotient venture capital transaction
Next: 11/14/2017: Loft Orbital venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs